THE INFLUENCE OF UNDERLYING PRETRANSPLANT DISEASE ON CARDIOTONIC AND VASOACTIVE THERAPY IN EARLY PERIOD AFTER HEART TRANSPLANTATION
https://doi.org/10.15825/1995-1191-2011-1-43-49
Abstract
In our study there were 56 patients (54 men and 2 female) in age from 16 to 61 (41,2 ± 2,7) years. Severity of CHF in 36 (64,3%) patients were corresponded III class NYHA, in 20 (35,7%) patients – IV class. 12 (15,5%) patients was in 1B status of UNOS, 44 (60,8 %) patients – in II status. In all cases biatrial technique of OHT was used, total ischemic time was 107–330 (170 ± 11) min. All recipients were divided on two investigate groups. In the 1-st group (n = 31) recipients with pretransplant ischemic cardiomyopathy (ICM ) were included, in the 2-nd group (n = 25) – recipients with pretransplant dilated cardiomyopathy (DCM). There was no difference bet- ween groups in basic preoperative characteristic, ischemic transplant time, duration of cardiopulmonary bypass, type and severity of cardiac transplant dysfunction. Our study showed that ICM-group patients had higher level indexed systemic vascular resistance since 3 postoperative day, required more frequent use of dobutamine and isorbide dinitrate for systemic and pulmonary hemodynamic management in this category of heart recipients. Also ICM-group patients had more preferable systemic hemodynamic conditions for application of prostaglan- din E1 in more effective doses.
About the Authors
V. N. Poptsov
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
Russian Federation
Russian Federation
O. V. Voronina
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
Russian Federation
Russian Federation
S. G. Uchrenkov
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
Russian Federation
Russian Federation
E. A. Spirina
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
Russian Federation
Russian Federation
A. I. Magilevetch
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
Russian Federation
Russian Federation
References
1. Казаков Э.Н., Кормер А.Я., Шемакин С.Ю. Отбор и подготовка больных к трансплантации сердца. В кн.: Трансплантация сердца. Руководство для врачей, под редакцией В.И. Шумакова. Москва, МИА. 2006. С. 30–45.
2. Bourge R.C., Kirklin J.K., Thomas K. et al. The emer- gences of co-morbid disease impacting survival after cardiac transplantation, a ten years multi-institutional experiences. //J. Heart Lung Transplant. 2001. Vol. 20 (2). P. 167–168.
3. Young J.B., Hauptman P.J., Naftel D.C. Determinants of early graft failure following cardiac transplantation, a 10-year, multi-institutional, multivariable analysis // J. Heart Lung Transplant. 2001. Vol. 20 (2). P. 212–216.
4. Захаревич В.М. Причины, лимитирующие длитель- ность выживания после трансплантации сердца: Дис. ... доктора мед. наук. Москва, 2008.
5. Kirklin J.K., Pambukian S.V., McGiffin D.C., Benza R.L. Current outcomes following heart transplantation // Semin Thorac Cardiovasc Surg. 2004. Vol. 16 (4). P. 395–403.
6. Kobashigawa J.A., Starling R.C., Mehra M.R. et al. Multicenter retrospective analysis of cardiovascular risk factor affecting long-term outcome of de novo cardiac transplant recipients // J. Heart Lung Transplant. 2006. Vol. 25 (9). P. 1063–1069.
7. Schanchez-Lazaro H., Martinez-Doltz L., Menair-Bo- net L. et al. Predictor factor for development of arteri- al hypertension following heart transplantation // Clin. Transplant. 2008. Vol. 22 (6). P. 760–764.
8. Takayma H., Nathens A.B., Merry H. et al. Is pre-trans- plant vascular disease a risk factor for mortality and mor-
9. bidity after heart transplantation // Eur. J. CardioThorac
10. Surg. 2007. Vol. 31. P. 457–461.
11. Pierce G.L., Schofield R.S., Nichols W.W. et al. Role of
12. heart failure etiology on arterial wave reflection in heart transplant recipients: relation with C-reactive protein // J. Hypertens. 2007. Vol. 25 (11). P. 2273–2279.
13. Patel A.R., Kuvin J.T., Pandian N.G. et al. Heart failure etiology affects peripheral vascular endothelial vascular function after cardiac transplantation // J. Am. Col Car- diol. 2001. Vol. 37 (1). P. 195–200.
14. Antanes M.J., Biernat M., Sola E. et al. Cardiac allograft systolic function. Is the aetiology (ischemic or idiopa- thic) a determinant of ventricular function in the heart transplant patient? // Interactive Cardiovascular and Thorac Surgery. 2008. Vol. 7. P. 586–590.
15. Chen E.P., Bittner H.B., Davis R.D., Van T.P. Hemodyna- mic and inotropic effects of milrinone after heart trans- plantation in the setting of recipient pulmonary hyper- tension // J. Heart Lung Transplant. 1998. Vol. 17 (7). P. 669–678.
16. Armitage J.M., Hardesky R.L., Griffith B.P. Prostaglan- din E1 an effective treatment of right heart failure after orthotopic heart transplantation // J. Heart Transpl. 1987. Vol. 6 (6). P. 348–351.
17. Weis C.I., Park J.V., Bolman R.M. Prostaglandin E1 for treatment of elevated pulmonary vascular resistance in patients undergoing cardiac transplantation // Transplant. Proc. 1989. Vol. 21. P. 2555–2556.
18. Mosquera I., Crespo-Leiro M.G., Tabuyo T. et al. Pulmo- nary hypertension and right ventricular failure after heart transplantation: usefulness of nitric oxide // Transplant. Proc. 2002. Vol. 34 (1). P. 166–167.
Review
For citations:
Poptsov V.N., Voronina O.V., Uchrenkov S.G., Spirina E.A., Magilevetch A.I. THE INFLUENCE OF UNDERLYING PRETRANSPLANT DISEASE ON CARDIOTONIC AND VASOACTIVE THERAPY IN EARLY PERIOD AFTER HEART TRANSPLANTATION. Russian Journal of Transplantology and Artificial Organs. 2011;13(1):43-49. (In Russ.) https://doi.org/10.15825/1995-1191-2011-1-43-49
Views:
864
Email this article 